HDAC9 and cancer: Advances in clustered regularly interspaced short palindromic repeat (CRISPR) and their associated protein (Cas9)-based epigenetic editing, combined with small molecule inhibitors like EZH2 or HDAC inhibitors, allow precise gene and epigenetic regulation, offering the potential for cancer and genetic disorder treatments.